153 related articles for article (PubMed ID: 8881897)
21. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
22. Cyclosporin A treatment in severe childhood psoriasis.
Pereira TM; Vieira AP; Fernandes JC; Sousa-Basto A
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):651-6. PubMed ID: 16836490
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
[TBL] [Abstract][Full Text] [Related]
24. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996.
Berth-Jones J; Voorhees JJ
Br J Dermatol; 1996 Nov; 135(5):775-7. PubMed ID: 8977680
[No Abstract] [Full Text] [Related]
25. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
Reitamo S; Spuls P; Sassolas B; Lahfa M; Claudy A; Griffiths CE;
Br J Dermatol; 2001 Sep; 145(3):438-45. PubMed ID: 11531834
[TBL] [Abstract][Full Text] [Related]
26. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.
Faerber L; Braeutigam M; Weidinger G; Mrowietz U; Christophers E; Schulze HJ; Mahrle G; Meffert H; Drechsler S
Am J Clin Dermatol; 2001; 2(1):41-7. PubMed ID: 11702620
[TBL] [Abstract][Full Text] [Related]
27. Cyclosporine in the treatment of psoriasis.
Gulliver WP
Cutis; 2000 Nov; 66(5):365-9. PubMed ID: 11107522
[TBL] [Abstract][Full Text] [Related]
28. Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series.
García-Bustínduy M; Escoda M; Guimerá FJ; Sáez M; Dorta S; Fagundo E; Sánchez-González R; Noda-Cabrera A; García-Montelongo R
J Eur Acad Dermatol Venereol; 2004 Mar; 18(2):169-72. PubMed ID: 15009296
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines.
Altomare G; Ayala F; Bardazzi F; Bellia G; Chimenti S; Colombo D; Flori ML; Girolomoni G; Micali G; Parodi A; Peris K; Vena GA
G Ital Dermatol Venereol; 2016 Aug; 151(4):432-5. PubMed ID: 25786483
[TBL] [Abstract][Full Text] [Related]
30. The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis.
Atakan N; Erdem C
J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):240-6. PubMed ID: 9883436
[TBL] [Abstract][Full Text] [Related]
31. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group.
Yocum DE; Allard S; Cohen SB; Emery P; Flipo RM; Goobar J; Jayawardena S; Job-Deslandre C; Jubb RW; Krüger K; Lopes Vaz A; Manger B; Mur E; Nygaard H; Weiner SM; Rainer F; Sack MR; Schiff MH; Schnitzer TJ; Trigg LB; Whatmough I; Schmidt AG
Rheumatology (Oxford); 2000 Feb; 39(2):156-64. PubMed ID: 10725065
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels.
Heydendael VM; Spuls PI; Ten Berge IJ; Opmeer BC; Bos JD; de Rie MA
Br J Dermatol; 2002 Jul; 147(1):122-9. PubMed ID: 12100194
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010.
Akasaka E; Mabuchi T; Manabe Y; Yahagi E; Yamada-Hiruma A; Yamaoka H; Kojima T; Kato M; Ikoma N; Ozawa A; Haruki Y
J Dermatol; 2013 Apr; 40(4):238-43. PubMed ID: 23330814
[TBL] [Abstract][Full Text] [Related]
34. Infant with generalized pustular psoriasis who responded to cyclosporin A therapy.
Takahashi M; Takeuchi M; Matsunaga K
J Dermatol; 2015 Sep; 42(9):911-3. PubMed ID: 26046589
[No Abstract] [Full Text] [Related]
35. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
Touw CR; Hakkaart-Van Roijen L; Verboom P; Paul C; Rutten FF; Finlay AY
Br J Dermatol; 2001 May; 144(5):967-72. PubMed ID: 11359382
[TBL] [Abstract][Full Text] [Related]
36. Generalized pustular psoriasis following a short course of cyclosporin (Neoral).
Mahendran R; Grech C
Br J Dermatol; 1998 Nov; 139(5):934. PubMed ID: 9892979
[No Abstract] [Full Text] [Related]
37. Cyclosporin for atopic dermatitis in children.
Harper JI; Berth-Jones J; Camp RD; Dillon MJ; Finlay AY; Holden CA; O'Sullivan D; Veys PA
Dermatology; 2001; 203(1):3-6. PubMed ID: 11549791
[TBL] [Abstract][Full Text] [Related]
38. The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis.
Ohtsuka T
Arch Dermatol Res; 2008 Nov; 300(10):545-50. PubMed ID: 18797895
[TBL] [Abstract][Full Text] [Related]
39. [Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation].
Humbert H
Therapie; 1997; 52(4):353-7. PubMed ID: 9437891
[TBL] [Abstract][Full Text] [Related]
40. Treatment of severe atopic dermatitis in childhood with cyclosporin.
Zaki I; Emerson R; Allen BR
Br J Dermatol; 1996 Sep; 135 Suppl 48():21-4. PubMed ID: 8881900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
